open access

Vol 58, No 5 (2007)
Review article
Published online: 2007-10-16
Submitted: 2013-02-15
Get Citation

Corticosteroids influence on angiogenesis in heart muscle

Jadwiga Jośko, Katarzyna Ratman, Rajmund M. Ratman
Endokrynologia Polska 2007;58(5):436-439.

open access

Vol 58, No 5 (2007)
Review article
Published online: 2007-10-16
Submitted: 2013-02-15

Abstract

The process of angiogenesis in a heart muscle is a way of providing the ischaemic myocardium with oxygen and nutritive ingredients. This natural process called therapeutic angiogenesis has been tried in the treatment of patients with coronary artery disease mainly. It has been seen as a chance of an effective beneficial therapy particularly in these patients for whom pharmacological treatment is not sufficient and who are disqualified for operative methods such as the percutaneus coronary angioplasty, or coronary bypass transplantation.
The goal of therapeutic angiogenesis is to stimulate the growth of new capillaries in a heart and, as a result, to improve the perfusion and function of a heart muscle.
The positive impact of the angiogenesis in a heart muscle is impeded in patients using corticosteroids in treatment for other illnesses. Corticosteroids inhibit the angiogenesis process on a cellular and tissue level. They decrease gene expression for VEGF, iNOS, inhibit the activity of transcriptive factors for AP-1 and NFkB. Corticosteroids cause the degradation of a pericellular matrix, inhibit the migration of macrophages and inhibit the synthesis of NO and interleukin. These activities of corticosteroids decrease the number of new vessels in a ischaemic miocardium and, consequently, worsen vascularization and progressive hypoxia.
(Pol J Endocrinol 2007; 58 (5): 436-439)

Abstract

The process of angiogenesis in a heart muscle is a way of providing the ischaemic myocardium with oxygen and nutritive ingredients. This natural process called therapeutic angiogenesis has been tried in the treatment of patients with coronary artery disease mainly. It has been seen as a chance of an effective beneficial therapy particularly in these patients for whom pharmacological treatment is not sufficient and who are disqualified for operative methods such as the percutaneus coronary angioplasty, or coronary bypass transplantation.
The goal of therapeutic angiogenesis is to stimulate the growth of new capillaries in a heart and, as a result, to improve the perfusion and function of a heart muscle.
The positive impact of the angiogenesis in a heart muscle is impeded in patients using corticosteroids in treatment for other illnesses. Corticosteroids inhibit the angiogenesis process on a cellular and tissue level. They decrease gene expression for VEGF, iNOS, inhibit the activity of transcriptive factors for AP-1 and NFkB. Corticosteroids cause the degradation of a pericellular matrix, inhibit the migration of macrophages and inhibit the synthesis of NO and interleukin. These activities of corticosteroids decrease the number of new vessels in a ischaemic miocardium and, consequently, worsen vascularization and progressive hypoxia.
(Pol J Endocrinol 2007; 58 (5): 436-439)
Get Citation

Keywords

corticosteroids; angiogenesis; heart muscle

About this article
Title

Corticosteroids influence on angiogenesis in heart muscle

Journal

Endokrynologia Polska

Issue

Vol 58, No 5 (2007)

Pages

436-439

Published online

2007-10-16

Bibliographic record

Endokrynologia Polska 2007;58(5):436-439.

Keywords

corticosteroids
angiogenesis
heart muscle

Authors

Jadwiga Jośko
Katarzyna Ratman
Rajmund M. Ratman

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl